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Introduction
Tumour invasion and metastasis require proteolytic degra-
dation of the extracellular matrix (ECM) and the base-
ment membrane to allow for the infiltration of tumour
cells into the surrounding tissue, the blood stream, and/or
into the lymphatic vessels [1]. At least four different types
of tumour-associated proteases may be responsible for
tumour stroma degradation and tumour cell invasion.
They are: cysteine proteases, aspartate proteases, matrix
metalloproteases and serine proteases [2]. The compo-
nents of the plasminogen activation system (urokinase
type plasminogen activator uPA, specific plasminogen
activator inhibitors PAI-1 and PAI-2 and the urokinase
receptor uPAR) released by cancer cells stimulate tumour
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I n t r o d u c t i o n.  High concentrations of plasminogen activator inhibitor 1 (PAI-1) are a poor predictive factor for colorectal
cancer patients. The PAI-1 gene is highly polymorphic and it is supposed that its variability could contribute to the level of the
PAI-1 biosynthesis.
M a t e r i a l  a n d  m e t h o d s.  We investigated the distribution of genotypes and frequency of alleles of the 1334G/A poly-
morphism in samples of cancer tissue, distant mucosa and in the blood of 100 patients with colorectal cancer. 1334G/A poly-
morphism was determined by PCR amplification using allele-specific primers.
R e s u l t s.  The distribution of the genotypes of 1334G/A polymorphism did not differ significantly (p>0.05) from that pre-
dicted by the Hardy-Weinberg equilibrium. There were no differences in genotype distribution between blood, normal mucosa
samples and cancer tissue. Additionally, we found no significant differences in frequencies alleles between colorectal cancer
subjects and controls (p>0.05).
C o n c l u s i o n.  Our results suggest that 1334G/A polymorphism of PAI-1 gene does not correlate with the development of col-
orectal cancer.
Polimorfizm 1334G/A genu inhibitora aktywatorów plazminogenu typu 1 (PAI-1) 
u chorych na raka jelita grubego
W s t ´ p.  Wysoki poziom inhibitora aktywatorów plazminogenu typu 1 (PAI-1) w raku jelita grubego jest zwiàzany ze z∏ymi pro-
gnozami dla pacjentów. Gen kodujàcy PAI-1 jest wysoce polimorficzny i przypuszcza si´, ˝e zmiennoÊç sekwencji genu mo˝e
wp∏ywaç na poziom biosyntezy PAI-1.
M a t e r i a ∏ y  i m e t o d y.  W obecnej pracy okreÊlono rozk∏ad genotypów i cz´stoÊci alleli polimorfizmu 1334G/A w guzie, pra-
wid∏owej b∏onie Êluzowej jelita oraz krwi u 100 chorych na raka jelita grubego. Polimorfizm 1334G/A by∏ analizowany przy
zastosowaniu reakcji PCR, z wykorzystaniem starterów allelospecyficznych.
W y n i k i.  Rozk∏ad genotypów polimorfizmu 1334G/A u pacjentów nie ró˝ni∏ si´ znaczàco (p>0.05) od rozk∏adu przewidy-
wanego przez prawo Hardy’ego-Weinberga. Nie by∏o znaczàcych ró˝nic w rozk∏adzie genotypów pomi´dzy krwià, tkankà
prawid∏owà, a guzem. Poza tym nie stwierdzono statystycznie istotnych ró˝nic w cz´stoÊci alleli pomi´dzy chorymi na raka jeli-
ta grubego, a grupà kontrolnà (p>0.05).
W n i o s e k.  Uzyskane wyniki sugerujà, ˝e polimorfizm 1334G/A genu PAI-1 mo˝e nie byç zwiàzany z wyst´powaniem raka
jelita grubego.
Key words: Plasminogen activator inhibitor 1 (PAI-1), 1334G/A polymorphism, colorectal cancer, PCR
S∏owa kluczowe: Inhibitor aktywatorów plazminogenu typu 1 (PAI-1), polimorfizm 1334G/A, rak jelita grubego, PCR
1 Laboratory of Molecular Genetics
Department of Pathology
Institute of Polish Mother’s Memorial Hospital, ¸ódê, Poland
2 Department of Molecular Genetics, University of ¸ódê, Poland
invasion [3]. High levels of uPA, uPAR and PAI-1 are
associated with poor prognosis in a number of malignan-
cies [4, 5].
Patients with colorectal cancer can be cured by sur-
gical treatment only if the cancer is detected at an early
stage [6]. It is therefore important to identify high-risk
or low-risk patients with the aid of suitable markers.
Many studies have shown that PAI-1 may be a useful
prognostic marker in colorectal cancer [7-11]. The ele-
vated level of PAI-1 can be associated with shorter recur-
rence-free survivals and shorter overall survivals. Changes
in PAI-1 biosynthesis are usually preceeded by changes in
its gene transcription and mRNA level [12]. Gene vari-
ability could contribute to the level of PAI-1 biosynthesis.
Ten different polymorphisms within the PAI-1 gene have
been described: A G substitution in position +1334 in
propeptide coding region, two (CA)n repeat polymor-
phisms, one in the promoter and one in the intron 4; the
HindIII restriction fragment length polymorphism; an
insertion (5G)/deletion (4G) polymorphism at position
– 675 of the PAI-1 gene promoter; two G A substitu-
tions at positions -844, and +9785; three polymorphisms
in the 3’ untranslated region: T G substitution at posi-
tion +11 053 and 9-nucleotide insertion/deletion located
between nucleotides +11 320 and +11 345 in a three-
fold repeated sequence, G A substitution in position
+12 078 [13-15].
In view of the potentially significant role of PAI-1
for tumour spread, it is important to determine whether
this polymorphism can account for the appearance and/or
development of colorectal cancer.
Among the polymorphic variants of the PAI-1 gene
an insertion (5G)/deletion (4G) polymorphism was stud-
ied most frequently. It is associated with high plasma
PAI-1 levels in patients with coronary artery disease [16,
17], myocardial infarction [18, 19] and diabetes [20, 21].
The role of 4G/5G polymorphism was also investigated in
subjects with breast [22, 23], endometrial [24] and col-
orectal cancer [25, 26] but no association was observed
between this sequence variation and cancer progression.
In our study we examined the relationship between
1334G/A polymorphism in the propeptide coding region
of the PAI-1 molecule and the appearance and/or inva-
siveness of colorectal cancer. It has been reported that
particular genotypes of 1334G/A polymorphism could be
associated with a tendency to haemorrhage [15], but little
is known about the possible role of this polymorphism
in cancer.
We focused on the distribution of genotypes and the
frequency of alleles of the 1334G/A polymorphism in
patients with colorectal cancer.
Materials and methods
Pa t i e n t s
Tumour tissue, distant mucosa samples and blood were obtained
from 100 patients (56 men and 44 women; mean age: 59 years;
range: 37-68 yrs.) with colorectal cancer treated at the 2nd
Department of Surgery of the Military Academy of Medicine in
¸ódê, Poland between 1997 and 2001. The patients’ clinical and
histopathological data was registered. All tumours were graded
according to Dukes’ stages: 29 in stage A, 50 in stage B and 21 in
stage C. Blood samples from age-matched healthy individuals
(n=106) served as control.
D N A  i s o l a t i o n
DNA from cancer tissue and distant mucosa samples was
extracted using the commercially available OIAmp Kit (Qiagen
GmbH, Hilden, Germany) DNA purification kit according to
manufacturer’s instruction. Blood was mixed with an equal vol-
ume of buffer containing 1% Triton X-100, 2% sarcosyl, 0.8 M
urea, 20 mM EDTA, 0.4 M NaCl, 200 mM Tris, pH 8.0, and
RNase A was added to a final concentration of 100 µg/ml. After
2h incubation at 55°C proteinase K was added to a final con-
centration of 125 µg/ml and incubation continued for another 2h,
then DNA was extracted: once with phenol and twice with chlo-
roform.
D e t e r m i n a t i o n  o f  t h e  1 3 3 4 G / A  p o l y m o r p h i s m
Genotypes of the 1334G/A polymorphism were determined by
polymerase chain reaction amplification of genomic DNA using
the following allele-specific primers: two 17-mer: 5’-TCA CCA
AAG ACA AGG GC-3’, and 5’-TCA CCA AAG ACA AGG
GT-3’ in combination with an upstream primer 5’- TGT TCA
CTT ACC ACC TGC TT -3’ [15]. The amplification resulted in
a DNA fragment of 182 bp and was performed in a total volume
of 25 µl. The PCR was carried out in a DNA Thermal Cycler
(GeneAmp PCR System 2400; Perkin-Elmer, Norwalk, CT,
U.S.A.). The thermal cycling conditions were 30 s at 94°C, 30 s at
60°C, 30 s at 72°C, repeated for 30 step cycles. The reaction
mixture contained 1 µg of genomic DNA, 0.2 µmol of each
appropriate primer (ARK Scientific GmbH Biosystems,
Darmstad, Germany), 2.5 mM MgCl2, 1 mM dNTPs (Qiagen
GmbH, Hilden, Germany) and 1 unit of Taq Polymerase (Qiagen
GmbH, Hilden, Germany). PCR products were electrophoresed
in a 5% polyacrylamide gel (PAGE) and visualised by ethidium
bromide staining (Figure 1). Each subject was classified into
one of the three possible genotypes: G/G, G/A or A/A.
S t a t i s t i c a l  a n a l y s i s
The allelic frequencies were estimated by gene counting and
genotypes were scored. The observed numbers of each PAI-1
genotype were compared with that expected for a population
acc. to the Hardy-Weinberg equilibrium by using the χ2 test.
The significance of the differences of observed alleles and geno-
types between groups was tested using the χ2 analysis.
Results
From the PCR analysis, all patients and controls were
classified into three genotypes of the 1334G/A polymor-
phism: G/G, G/A and A/A (Figure 1).
Table I shows genotype distributions in normal
mucosa samples, tumour tissue and blood. The dis-
tributions of the genotypes and the frequencies of the A
and G alleles did not differ significantly (p>0.05) from
those predicted by the Hardy-Weinberg equilibrium.
Additionally, there were no differences in the frequencies
of the A (0.51) and G (0.49) alleles between blood,
healthy tissue and cancer tissue.
The distributions of the G/A genotypes, as well as
the frequencies of the A and G alleles for colorectal can-
cer patients and control, are shown in Table II. It can be
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seen that there were no significant differences (p>0.05)
between the investigated groups. Frequencies of the A
and G allele were 0.51/0.49 in cancer patients and
0.42/0.58 in controls. Among cancer patients the observed
frequencies of the G/G, G/A and A/A genotype did not
differ significantly (p>0.05) from the distribution expect-
ed from the Hardy-Weinberg equilibrium.
The dependencies of the distribution of genotypes
and frequencies of alleles on the tumour grade evaluated
according to Dukes’ criteria of patients with colorectal
cancer are displayed in Table III. There were no signifi-
cant differences between the distribution of genotypes
in subgroups assigned to histological stage and the distri-
bution predicted by the Hardy-Weinberg equilibrium
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Figure 1. A typical result of allele specific polymerase chain reaction performed with fragment of the promoter of PAI-1 gene and analysed by a 5%
polyacrylamide gel electrophoresis, staining with ethidium bromide and viewed under ultraviolet light. Lanes 1, 3, 5 and 7 display the product of
amplification with a primer specific to the A allele; lanes 2, 4, 6 and 8 – the G allele; M – molecular weight marker, 50-2000 bp (Sigma, St. Louis, USA)
Table I. Distribution of G/G, G/A and A/A genotypes and frequencies of the G and A alleles in blood, tumour tissue 
and in distant mucosa of patients with colorectal cancera
Blood Tumour tissue Distant mucosa
number frequency number frequency number frequency
A/A genotype 31 0.31 31 0.31 31 0.31
G/A genotype 40 0.40 40 0.40 40 0.40
G/G genotype 29 0.29 29 0.29 29 0.29
χ2 3.987b
A allele 102b 0.51 102 0.51 102 0.51
G allele 98 0.49 98 0.49 98 0.49
an = 100; bp>0.05 as compared with Hardy-Weinberg distribution
Table II. Distribution of G/G, G/A and A/A genotypes and frequencies of the G and A alleles in patients with colorectal cancer and controls
Patients (n = 100) Controls (n = 106)
number frequency number frequency
A/A genotype 31 0.31 21 0.20
G/A genotype 40 0.40 48 0.45
G/G genotype 29 0.29 37 0.35
χ2 3.987a 0.591a
A allele 102 0.51b 90 0.42
G allele 98 0.49b 122 0.58
ap>0.05 as compared with Hardy-Weinberg distribution; bp>0.05 as compared with the controls
(p>0.05). Neither were there any differences in the fre-
quencies of the A and G alleles between the subgroups
(p>0.05).
Discussion
Genetic factors have been shown to influence the pro-
tein level of several haemostatic factors. The 1334G/A
polymorphism of the PAI-1 gene has been associated with
interindividual differences in the basal steady state level of
its protein [27]. In addition, responses to environmental
factors have been shown to differ by genotype [28].
In this study we have shown on a group of 100
patients that there is no association between the geno-
types of the 1334G/A polymorphism of PAI-1 gene and
the appearance of colorectal cancer. Moreover, we did
not detect any significant difference between genotypes in
subgroups assigned to histological stages. This suggests
a lack of association between gene polymorphism and
colorectal cancer invasiveness. Previously we have shown
a similar relationship for 4G/5G and -844G/A polymor-
phism of PAI-1 gene for breast and colorectal cancers
[23, 25, 26].
The 1334G/A polymorphism was found to be asso-
ciated with severe bleeding problems, similar to those
seen in patients with haemophilia [15], but no data is
available on the association, or lack of such association, in
colorectal cancer. Because the recent years have brought
a development in the understanding of the prognostic
values of the components of the plasminogen activation
system in cancer progression, it is important to know
whether polymorphic variants of the genes encoding the
components can be considered as markers of appearance
and/or progression of cancer.
It should also be considered that, in addition to
genotype, a series of environmental factors affect plasma
PAI-1 levels. PAI-1 synthesis has been related to high
serum concentrations of glucose, insulin and triglicerydes
[29], sex hormone [30] and angiotensin [31]. An increased
level of PAI-1 can be also linked with smoking habits [32],
alcohol consumption [33] and acute infections [34].
The expression of PAI-1 undergoes changes during
a variety of pathological processes, including cancer inva-
sion and metastasis. The consequence of altered gene
expression is the usually elevated level of PAI-1 protein
observed in cancer. It is probable that gene variability
could contribute to the level of PAI-1 biosynthesis 
[35].
In the analysis of the exons of the PAI-1 gene only
one base change was identified at base pair number 1334
(number according to Bosma et al.) [35], where both G
and A were present. The base change (G1334 A) caus-
es a change of alanine at residue -9 in the propeptide of
PAI-1 molecule to threonine. It is known that 1334G/A
polymorphism is associated with the PAI-1 gene activity
under interleukin-1 stimulation, that may influence the
transcription of the gene [36]. Such influence is regulated
by cytokines which are released by tumour cells.
Our study implies that the 1334G/A polymorphism
of the PAI-1 gene may not be directly involved in the
development of colorectal cancer. However, further
research conducted on a larger population is needed to
clarify this tentative conclusion.
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